Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

BACKGROUND: Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here, we report primary results from a blinded phase 3 study evaluating the efficacy and safety of pre-exposure prophylaxis (PrE...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Kenneth H, Molina, Jean-Michel, Thompson, Melanie A, Anderson, Peter L, Mounzer, Karam C, De Wet, Joss J, DeJesus, Edwin, Jessen, Heiko, Grant, Robert M, Ruane, Peter J, Wong, Pamela, Ebrahimi, Ramin, Zhong, Lijie, Mathias, Anita, Callebaut, Christian, Collins, Sean E, Das, Moupali, McCallister, Scott, Brainard, Diana M, Brinson, Cynthia, Clarke, Amanda, Coll, Pep, Post, Frank A, Hare, C Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665936/
https://www.ncbi.nlm.nih.gov/pubmed/32711800
http://dx.doi.org/10.1016/S0140-6736(20)31065-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665936/
https://www.ncbi.nlm.nih.gov/pubmed/32711800
http://dx.doi.org/10.1016/S0140-6736(20)31065-5

Ejemplares similares